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Increased Epstein-Barr virus (EBV) replication has 
been reported in the salivary and lacrimal glands 
in Sjogren's syndrome (SS). We studied whether 
or not certain EBV strains would occur preferen- 
tially in the peripheral blood and parotid gland sa- 
liva of 18 EBV-seropositive patients with primary 
Sjogren's syndrome (pSS) and 12 EBV-seroposi- 
tive control persons. Transforming EBV was de- 
tected in the blood of 11 of 18 (61%) pSS patients 
and 9 of 12 controls (75%). Unexpectedly, neither 
transforming nor Raji-superinfecting EBV strains 
were detected in SS parotid saliva, whereas these 
EBV types were detected in control saliva in 7 and 
8 cases, respectively (P < 0.001). Transforming 
EBV strains were further characterized by 'Ebno- 
typing,' i.e., analysis of the size spectrum of the 
viral antigens EBNA 1, 2,3, and 6 in immunoblots 
of lymphoblastoid cell lines (LCL). Previous work 
has shown that a single EBV strain (Ebnotype) 
dominates the blood and oropharynx of healthy 
carriers and that unrelated individuals carry differ- 
ent EBV strains, reflecting the vast polymorphism 
of Ebnotypes in the general population. Two unex- 
pected observations were made. First, an identical 
Ebnotype was detected in 4 unrelated individuals, 
i.e., in the blood of 1 pSS patient and in the saliva 
of 3 control persons. Second, carriage of 2 to  4 
different Ebnotypes by a single individual was ob- 
served in 4cases. i.e., in  the blood of 1 pSS patient, 
and in the blood and saliva of 3 control persons. As 
only 1 control person had received a blood transfu- 
sion, it is suggested that (supedinfection with ex- 
ogenous EBV strains via salivary transmission 
and/or recombination of endogenous virions may 
have contributed to this situation. 
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INTRODUCTION 
Epstein-Barr virus (EBV) is a ubiquitous herpesvirus 
that spreads through populations by salivary contact. 
EBV preferentially infects 2 cell types: the B lympho- 
cytes, where the infection is largely nonproductive 
[Nilsson et al., 19711, and stratified squamous epithelia 
in which EBV replication occurs [Sixbey et  al., 19841. 
Intense replication of EBV in epithelial cells is accom- 
panied by the presence of EBV deletion mutants [Pat- 
ton et al., 1988; Sixbey et al., 19911. Such deletions 
have a profound impact on the biological properties of 
the virus. The archetypal EBV biotype, B95.8, has been 
isolated from lymphocyte cultures and is capable to 
immortalize B lymphocytes into permanent lympho- 
blastoid cell lines (LCL) [Miller et al., 19741. Such LCL 
carry EBV genomes persistently; they express the 
growth transformation-associated nuclear proteins 
EBNA 1 to 6 and the membrane-associated proteins 
LMP 1 and LMP 2 [Kieff and Liebowitz, 19901. Among 
these proteins EBNA 2 plays a key role in lymphocyte 
transformation [Cohen et  al., 19891. EBNA 2 deletion 
variants, represented by the P3HR-1 strain, produce 
abortive infections without assembly of mature virions 
and can be detected by their ability to induce early 
antigens (EA) in the EBV-carrying Burkitt's lym- 
phoma cell line Raji [Hinuma et al., 19671. EBV strains 
may also be categorized into Type A or Type B based on 
the organization of their BamHI WYH and E gene re- 
gions. The differences between these 2 types arise from 
sequence divergence within the open reading frames 
encoding EBNA 2 ,  3, 4, and 6 [Adldinger et al., 1985; 
Rowe et al., 19891. Type A EBV strains transform B 
lymphocytes efficiently, whereas Type B strains do so 
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poorly [Rickinson et al., 19871. A wide variety of Type A 
and B strains can be distinguished on the basis of size 
variations of EBNA 1 to 6 in immunoblots (‘Ebnotyp- 
ing’) [Gratama et al., 1990a,b, 19921. Coinfection with 
multiple EBV strains including A and B types is rare in 
healthy carriers but relatively frequent in immunodefi- 
cient patients such as human immunodeficiency virus 
(H1V)-infected individuals [Sixbey et al., 1989; Sculley 
et al., 19901 and bone marrow transplant recipients 
[Gratama et al., 19921. 
Sjogren’s syndrome ( S S )  is a systemic autoimmune 
disease characterized by the simultaneous presence of 
dryness of the mouth (xerostomia and eyes (keratocon- 
junctivitis sicca) associated with lymphocytic infiltra- 
tion of the salivary and lacrimal glands. The term ‘sec- 
ondary Sjogren’s syndrome’ is used when objective 
evidence of xerostomia and keratoconjunctivitis sicca is 
associated with an already well estabished autoim- 
mune disease such as rheumatoid arthritis or systemic 
lupus erythematosus. Otherwise the disease is termed 
primary Sjogren’s syndrome (pSS) [Moutsopoulos et al., 
19801. In salivary glands of SS patients, EBV DNA was 
detected in the nuclei of epithelial cells lining ducts and 
acini, which also expressed the replicative cycle EBV 
early antigen (EA) [Venables et al., 19891. SS salivary 
glands contained increased levels of EBV DNA in com- 
parison to normal salivary glands as detected by slot 
blot hybridization [Fox et al., 19861 and polymerase 
chain reaction (PCR) [Saito et al., 19891. EBV was de- 
tected predominantly in the epithelial cells of SS glands 
rather than in the lymphocytic infiltrate [Fox et al., 
1986; Schuurman et al., 1989; Venables et al., 1989; 
Mariette et al., 19911, in which activated T lymphocytes 
of the helper phenotype (CD3+, 4+, 38+, HLA - DR+) 
predominated [Adamson et al., 19831. These combined 
data indicate that EBV replication is increased in the 
glandular epithelia of SS patients. 
We investigated whether or not EBV replicative ac- 
tivity in the parotid gland epithelia of pSS patients was 
associated with the occurrence of multiple EBV bio- 
types in salivary gland excretions. Therefore, we com- 
bined Ebnotyping studies of transforming EBV with 
EA-induction assays of Raji cells to detect Raji-superin- 
fecting EBV. 
PATIENTS AND METHODS 
Patients 
Peripheral blood and parotid salivary samples were 
obtained from 18 patients diagnosed with pSS (all 
women; mean age 60 years [SD 12 years]; referred to as 
P1 to P18) and 12 control persons (all women; mean age 
60 years [SD 13 years]; referred to as C19 to C30). All 
patients and control persons were IgG seropositive for 
the viral capsid antigen of EBV. The patients met all of 
the following criteria for pSS: 1) subjective evidence of 
dryness of the eyes and mouth; 2) a t  least 2 positive 
diagnostic tests for keratoconjunctivitis sicca [Man- 
thorpe et  al., 19861; 3) more than 1 focus of 50 or greater 
mononuclear cells per 4 sq mm salivary gland tissue 
from the lower lip and/or a n  abnormal parotid gland 
sialography; and 4) the presence of serum rheumatoid 
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factor and/or antinuclear antibodies and/or anti-SS-A 
andlor anti-SS-B antibodies. None of the patients ful- 
filled the established criteria for another connective 
tissue disease. The control persons were seen for nonin- 
flammatory rheumatoid conditions a t  the Outpatient 
Rheumatology Clinic. Secretion of parotid saliva was 
stimulated at least 1 hour after a meal by application of 
citric acid under the tongue every 30 seconds over 10 
minutes. Parotid saliva was collected with a cup placed 
over the opening of Stensen’s duct preventing the ad- 
mixture of citric acid and saliva from other sources. 
From 8 patients, additional tongue scrapings and 
mouthwashes were obtained prior to citric acid stimu- 
lation. Tongue scrapings were resuspended in 10 ml 
RPMI 1640 medium. Mouthwashes were obtained by 
gargling for 1 min with 10 ml RPMI 1640 medium. 
Prior to setting up assays to detect transforming EBV 
(on the same or following day), bacteria and debris were 
removed from all oropharyngeal specimens and 10% 
(v/v) fetal calf serum (FCS) was added. The remainders 
of the oropharyngeal specimens were cryopreserved at 
-80°C until their use in the EA induction and PCR 
assays. 
Detection of Transforming EBV 
Peripheral blood mononuclear cells (PBMC) were iso- 
lated from heparinized blood samples and cultured in 
96-well flat-bottomed microtiter plates for 8 to 12 
weeks to obtain LCL [Gratama et al., 1990bI. Within 1 
week after initiation of the cultures, 100,000 fresh cord 
blood mononuclear cells were added to each well in 
order to rescue EBV released from virus-carrying cells 
[Lewin et al., 19871. For lymphocyte transformation 
assays by oropharyngeal specimens, 12 million cord 
blood mononuclear cells were incubated for 3 to 6 hours 
with undiluted 3 ml aliquots of the mouthwashes or 
tongue scrapings, and with 3 ml aliquots of 1:lO dilu- 
tions of parotid gland salivary samples in RPMI 
1640 + 10% FCS. Thereafter, the cells were washed 
and cultured for 8 to 12 weeks in 96-well flat-bottomed 
microtiter plates [Gratama et al., 1990bl. In order to 
allow the detection of multiple strains of transforming 
EBV from a single specimen by immunoblotting (see 
below), wells with growing cells were harvested and 
expanded individually from these 2 types of cultures. 
Detection of Raji-Superinfecting EBV 
Oropharyngeal specimens were diluted 1:2 in RPMI 
1640 + 10% FCS, sonicated for 10 seconds to release 
intracellular virions and filtered through 0.2 pm filters 
before inoculation. Exponentially growing, EA-D nega- 
tive Raji cells were resuspended to 0.5 x lo6 cells in 0.5 
ml RPMI 1640 + 10% FCS per flat bottom centrifuge 
tube, followed by addition of 0.5 ml of the filtered sam- 
ple and centrifugation at 4,OOOg at 35°C for 40 minutes. 
After resuspending the cells, 2.0 ml RPMI 1640 + 10% 
FCS were added to each tube, followed by incubation 
for 96 hours. Thereafter, the cells were spun down, con- 
centrated to 1/100th of the original volume and spread 
onto 6 coverslips (50 sq mm each). The cells were then 
air dried, fixed with acetone and stained with a human 
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TABLE I. EBV Detection in pSS Patients and Control Persons 
Sampling site EBV detection assay pSS patients Control persons 
Peripheral blood Transforming 11/18 (61%) 9/12 (75%) 
Stensen’s duct Transforming 0117 7/12 (58%) 
Raji-superinfecting 0117 8/12 (67%) 
Tongue Transforming 0/8 ND“ 
Raji-superinfecting 1/8 (13%) ND 
PCR 1/8 (13%) ND 
Mouthwash Transforming 018 ND 
Raji-superinfecting 018 ND 
PCR 115 (20%) ND 
“ND, not done 
serum positive for anti-EA-D antibodies but negative 
for EBNA antibodies. The number of EA-D+ cells were 
counted in quadruplicates. Uninfected Raji control cul- 
tures, processed in parallel, contained fewer than 2 
EA-D+ cells per cover slip. A culture yielding 5 times 
or more EA-D+ cells than the uninfected control was 
considered positive for Raji-superinfecting EBV 
strains. 
PCR 
Primers and Taq polymerase were obtained from 
Scandinavian Gene Synthesis Systems (Enkoping, 
Sweden) for use in a nested PCR. The sequence of the 
primers was derived from a conserved part of the EBNA 
1-coding BKRFl gene outside the Gly-Ala repeat that 
varies between wild-type EBV strains [Hennessy and 
Kieff, 19831. The sequence of the outer primers, i.e., 
5’AAGGAGGGTGGTTTGGAAAG3’ and 5’AGA- 
CAATGGACTCCCTTAGC3’, corresponded to B95.8 
coordinates 109,332 to 109,351 and 109,609 to 109,628, 
respectively. The sequence of the inner primers, i.e., 
5’ATCGTGGTCAAGGAGGTTCC3’ and 5’ACT- 
CAATGGTGTAAGACGAC3’ corresponded to B95.8 
coordinates 109,353 to 109,372 and 109,542 to 109,561, 
respectively [Baer et al., 19841. DNA was prepared by 
adding 0.1 ml lysis buffer to 0.1 ml oral specimen, fol- 
lowed by a 60-minute incubation at 55°C and a subse- 
quent 15-minute incubation at 95°C. Ten p1 of the ly- 
sates were first amplified for 20 cycles by the outer 
primer pair, followed by amplification in a nested PCR 
for 30 cycles using the inner primer pair. The final PCR 
products were visualized by electrophoresis in a 2% 
agarose gel, ethidium bromide staining, and photogra- 
phy using a Polaroid camera. A 170-bp fragment was 
considered specific for EBV. The B95.8-transformed 
LCL ZV18 was used as positive control and the EBV- 
negative cell lines BL41 and HSB2 were used as nega- 
tive controls. 
Immunoblotting 
Aliquots corresponding to 1 million LCL dissolved in 
electrophoresis sample buffer were loaded per lane for 
electrophoresis in gels containing 7.5% polyacrylamide 
and sodium dodecyl sulfate. The electroblotting proce- 
dure and the immunological detection of the EBNA 
proteins on the nitrocellulose filters was performed as 
described previously [Gratama et al., 1990bl. 
For the characterization of wild-type EBV strains on 
the basis of their different patterns of size of their nu- 
clear antigens EBNA 1, 2, 3, 4, and 6 (‘Ebnotyping’), 
serum from a patient with chronic lymphocytic leuke- 
mia [Lewin et al., 19881 was used at a 1:20 dilution for 
the detection of EBNA 1 ,2 ,3 ,4 ,  and 6. This serum also 
reacted with EBNA 5, seen as multiple weak bands in 
the 22 to 90 kD region. EBNA 1 and 2 were allocated to 
their specific bands using monospecific reagents. For 
EBNA 1, serum JF absorbed with Ramos cells was 
used, and for EBNA 2, monoclonal antibody (mAb) PE2 
[Young et al., 19891. Serum MSt, containing EBNA and 
EBNA 6 antibodies, was used for the selective detection 
of EBNA 6. The EBNA 1 antibodies did not interfere 
with the detection of EBNA 6 since the estimated 
mouthwash (MW) of the EBNA 1 protein never ex- 
ceeded 100 kD and the MW of EBNA 6 ranged between 
140 and 180 kD. The PE2 and MSt reagents were kind 
gifts of Dr. M. Rowe (Birmingham, UK). LMP 1 was 
detected using the ,512 mAb (a kind gift of Dr. D. Thor- 
ley-Lawson, Boston, MA). 
For the detection of EBNA antibodies in patient sera 
with high-titered BJA-B antibodies, a panel of 2 EBV- 
negative Burkitt’s lymphoma cell lines (BJA-B and 
Ramos), 3 LCL-carrying Type A EBV (TC 6 DOU, TC 
287 DON and TC 362 REN), and 2 LCL-carrying Type 
B EBV (TC 3 KOE and TC 287 VOS) were used. The 
size of the EBNA proteins of these LCL had been deter- 
mined using monospecific sera (see above and Gratama 
et al. [1990a]). The use of these cell lines allowed the 
distinction between serological reactivities with the 
EBNA 1,2,3,  and 6 proteins and EBV-nonspecific reac- 
tivities in most cases. The reactivities of the sera were 
scored on the basis of the intensity of each EBNA band, 
ranging from - (negative) to ++++ (strongly posi- 
tive). The reactivities of sera with Type A versus Type 
B EBV strains could also be determined, since large 
antigenic differences exist between the EBNA 2 and 6 
proteins of both types of EBV strains [Rowe et al., 
19891. 
RESULTS 
EBV Detection 
pSS patients and control persons showed similar fre- 
quencies of spontaneously outgrowing LCL from the 
blood: 11 of 18 (61%) pSS patients and 9 of 12 (75%) 
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TABLE 11. Characterization of Transforming EBV Strains 
Patient Assay for transforming EBV Expansion Immunoblotting 
or control # wells # wells wi # LCL Type and # of 
person a plated outgrowthb established" EBV strains 
P1 (PB) 
P2 (PB) 
P3 (PB) 
P4 (PB) 
P5 (PB) 
P8 (PB) 
P9 (PB) 
P10 (PB) 
P12 (PB) 
P14 (PB) 
P17 (PB) 
C19 (PB) 
C20 (PB) 
C20 (SA) 
C21 (SA) 
C22 (PB) 
C22 (SA) 
C24 (PB) 
C24 (SA) 
C25 (PB) 
C25 (SA) 
C26 (PB) 
C27 (PB) 
C27 (SA) 
C29 (PB) 
C30 (PB) 
C30 (SA) 
60 
60 
60 
60 
60 
120 
60 
120 
60 
60 
60 
60 
60 
60 
60 
60 
60 
60 
60 
60 
60 
60 
60 
60 
60 
60 
60 
17 (28%) 
3 (5%)) 
2 (3%) 
16 (27%) 
4 (7%) 
54 (45%) 
1(2%) 
14 (12%) 
5 (8%) 
3 (5%) 
9 (15%) 
3 (5%) 
4 (7%) 
3 (5%) 
2 (3%) 
58 (97%) 
2 (3%) 
4 (7%) 
2 (3%) 
16 (27%) 
2 (3%) 
2 (3%) 
1(2%) 
5 (8%) 
13 (22%) 
3 (5%) 
3 (5%) 
2 (12%) 
0 
0 
1(6%) 
0 
7 (13%) 
0 
8 (57%) 
0 
2 (67%) 
0 
1(33%? 
0 
1(33%) 
1(50%) 
24 (41%) 
0 
3 (75%) 
0 
8 (50%) 
1(50%) 
2 (100%) 
1 (100%) 
1(13%) 
7 (54%) 
2 (67%) 
0 
1 A-strain 
1 A-strain 
2 A-strains 
1 A-strain 
1 A-strain 
1 A-strain 
1 A-strain 
1 A-strain 
1 A-strain 
3 A-strains 
4 A-strains 
1 A-strain 
2 A-strains 
1 A-strain 
1 A-strain 
"Sampling site between brackets (PB, peripheral blood; SA, parotid saliva). 
bBetween parentheses: percentage of wells showing outgrowth (expressed as fraction of the number of 
plated wells). 
'Between parentheses: percentage of wells from which long-term growing LCL could be established 
(expressed as fraction of the number of wells showing outgrowth). 
controls (Table I). The proportion of wells showing out- 
growth per positive culture was also similar in both 
groups (Table 11): pSS patients, median 8% (range 
245%); control persons, median 7% (range 2-97%). In 
contrast, neither transforming nor Raji-superinfecting 
EBV was detected in the parotid saliva of any of 17 pSS 
patients, whereas transforming EBV was detected in 7, 
and Raji-superinfecting EBV in 8 of 12 control persons 
(Table I; P < 0.001 in both instances; 2-sided Fisher's 
exact test). The assays for transforming and Raji-super- 
infecting EBV in parotid saliva of pSS patients and 
control persons showed significant concordance (Table 
I): 6 of 7 samples positive for transforming EBV were 
also positive for Raji-superinfecting EBV, whilst 20 of 
22 samples negative for transforming EBV also yielded 
negative results for Raji-superinfecting EBV 
(P < 0.001). We then investigated whether or not EBV 
shedding from other sites in the oropharyngeal cavity 
of the pSS patients was also impaired. Parallel EBV 
detection assays were set up from tongue scrapings, 
mouthwashes, and parotid salivary samplings in  8 pa- 
tients. Again, all assays were negative, with the excep- 
tion of a positive culture of Raji-superinfecting EBV 
from the tongue-scraping of P15. Finally, EBV detec- 
tion was attempted by PCR in 8 tongue scrapings and 5 
mouthwashes. The PCR results of the tongue scrapings 
were completely concordant with those of the Raji-su- 
perinfection assays: only P15's tongue-scraping was 
positive. The PCR on the 5 mouthwashes was negative 
with the exception of a positive result on the mouth- 
wash of P8. 
EBV Serotyping 
The unexpected low frequency of detection of trans- 
forming EBV in the pSS patients may be due to their 
preferential carriage of Type B EBV strains which are 
poorly transforming [Rickinson et al., 19871. We inves- 
tigated this possibility by extrapolating the carrier sta- 
tus of Type B EBV strains from the detection on immu- 
noblots of an  EBNA antibody pattern specific for Type 
B EBV strains. Immunoblots reacting with the 18 pSS 
sera were readily interpretable in spite of EBV-nonspe- 
cific reactivities. Example immunoblots of sera from 2 
pSS patients (P8 and P12), both reactive with the EBV- 
negative cell lines BJA-B and Ramos, are shown in 
Figure 1. The P8 serum contained antibodies to Type A 
but not Type B EBV, as evidenced by the selective rec- 
oginition of EBNA 2 and 6 of the LCL-carrying Type A 
virus. Patient 12 had antibodies to Type B but not Type 
A EBV, as evidenced by: a) the stronger reactivity with 
Type B as compared to Type A EBNA 2; b) the nonreac- 
tivity with Type A EBNA 6; and c) the recognition of 1 
to 4 bands between 140 and 180 kD in Type B EBV- 
carrying LCL. Using these criteria, 11 of the 18 pSS 
sera were reactive with Type A and 4 with Type B EBV. 
The EBNA 2 and 6 antibody titers in the remaining 3 
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Fig. 1. Immunoblot probed with the sera from patients P8 (left 
panel) and P12 (right panel). Numbers in the middle indicate MW in 
kD. The EBV-negative BJA-B and Ramos cell lines were used as 
negative controls. EBNA 1 (indicated in the figure as b), 2 ( D), 3 0)  
and 6 (0) were assigned to their corresponding bands after probing 
with monospecific antisera (see Patients and Methods and Gratama et  
al. [1990b). The P8 serum was reactive with EBNA 1,2,3, and 6 ofthe 
sera were too low to allow the assessment of their reac- 
tivity patterns (Table 111). 
Characterization of Wild-Type Transforming 
EBV Strains 
Wells with growing cells were harvested separately, 
followed by expansion of the resulting LCL to allow 
Ebnotyping. LCL were established with significantly 
lower efficiency from the blood of the pSS patients than 
from that of the control persons (Table 11): LCL were 
successfully established from only a minority of wells 
with growing cells (median 0%; range 0-67%) in the 
pSS patients versus 54% (range 0-100%) in the control 
persons (P = 0.02 with Wilcoxon’s 2-sample test). 
LCL from the blood of 5 pSS patients and 8 control 
persons, and from the saliva of 4 control persons were 
expanded sufficiently to allow Ebnotyping (Table I1 and 
Fig. 2). All LCL carried Type A EBV strains. No LCL 
was established from any of the 4 patients with Type B 
EBNA antibodies (P6, P7, P11, and P12). Thus, our 
culture system may have selected against Type B EBV 
strains. Two unexpected observations were made. First, 
Type A strains and only with EBNA 1 of the Type B strains. The P12 
serum was a) strongly reactive with Type B EBNA 2 and showed 
weaker reactivity with Type A EBNA 2; b) nonreactive with Type A 
EBNA 3 and 6, hut recognized 4 bands in the 140-180 kD range in TC 
287 VOS (Type B); and c) similarly reactive with Type A and B EBNA 
1 proteins. 
a single EBV strain was shared by 4 unrelated individ- 
uals: the Ebnotype expressed by LCL G8 derived from 
the blood of P8 was also detected in LCLs G8, D11, and 
B10 derived from the saliva of C20, C21, and C25, re- 
spectively (Fig. 2). Second, simultaneous carriage of 2 
to 4 Type A EBV strains was observed in 4 cases (Pa, 
C24, C25, and C27; Table IV and Fig. 2). The MW of 
EBNA 1, 2, 6, and LMP 1 were estimated after immu- 
noblotting with monospecific reagents as  set out in Ta- 
ble IV. The 2 Ebnotypes identified in P8 and C27 dif- 
fered in all 4 proteins in both cases. Three Ebnotypes 
were identified in C24. LCL E l 0  expressed an  Ebnotype 
that differed only in EBNA 6 from that of LCL DlO, 
whilst the Ebnotype of LCL F7 differed in all 4 proteins 
from D10, but its EBNA 6 was similar to that of ElO. 
C25, the only individual with a positive blood transfu- 
sion history, showed the largest heterogeneity in Ebno- 
types. Six of the 8 LCL derived from her peripheral 
blood carried the G6 Ebnotype. The remaining 2 LCL 
shared only a single protein with G6, as did the LCL 
established from her parotid saliva culture: EBNA 2 of 
LCL D9, and LMP 1 of €35 and B10 were of the same size 
as the respective proteins of LCL G6. 
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TABLE 111. Detection of EBNA Antibodies in Sera From 
pSS Patients by Immunoblotting* 
Patient EBNA 1 EBNA 2A EBNA 2B EBNA 3 EBNA 6 
1 ++++ ? + ++ (A) 
2 (act) ++++ + + + (A) 
+ (A) 3 (act) +++ (+I  
4 +++ + 
5 ++++ + 
6 ++++ ( + I  + + + (B) 
++++ + ++ + + (B) 
8 (act) ++++ ++ + + (A) 
7 
++ (A) 
9 
10 ++++ +++ 
++ (B) 11 ++++ + ++ 
+++ (B) 12 ++++ + ++ 
++++ ++ + + + + ( A )  
14 ++++ ++ + +++ (A) 
13 
++ (A) 15 ++++ ++ ++++ ++ +++ +++ (A) 
++ (A) 
16 
+++ ++ 
+ (A) 
17 
18 (act) + ++ 
- 
- 
- - 
- - - 
- - - 
- 
- - - ++++ + 
- - 
- 
- 
~ 
- 
- - 
- 
- - 
- - 
*Reactivities of the sera were scored on the basis of the intensity of each EBNA band, ranging from - 
(negative) to + + + + (strongly positive). (act), serological evidence of chronic active EBV infection as 
indicated by the presence of IgA VCA antibodies, high titers (i.e., >1280) of IgG VCA antibodies, and/or 
the presence of any type of EA antibodies. (A) or (B), reactive with LCL carrying Type A or B EBV 
strains, respectively. 
Fig. 2. Immunoblots probed with the polyspecific PG serum [Lewin 
et al., 19881. Numbers on the right of each blot indicate MW in kD. The 
origin of the LCL (i.e., patient [PI or control [Cl; peripheral blood [PB] 
or saliva [SV]) are indicated above the lanes. BJA-B was used as 
negative control. Multiple LCL from a single individual are identified 
by their microtiter plate well numbers. All EBV strains were of Type 
A. They were all different with the exception of P8 PB[G8] which was 
identical to C20 SV, C21 SV, and C25 SV. E, EBNA. 
DISCUSSION 
Unexpectedly, the pSS patients distinguished them- 
selves from the control persons in the absence of trans- 
forming and Raji-superinfecting EBV in their parotid 
gland saliva. Additional samplings from tongue and 
mouthwash were also negative with two exceptions. 
The latter result is clearly at variance with that of 
Miyasaka et al. [1989] who isolated transforming EBV 
from the mouthwashes of 25 of 29 patients. We have no 
other explanation for the difference between our results 
and those of Miyasaka et al. [19891 other than patient 
selection. The absence of transforming activity and the 
almost complete absence of Raji-superinfecting activity 
may reflect very low or absent EBV concentrations in 
the oral specimens of our patients. This contention is 
supported by the result that 11 of the 12 oral specimens 
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TABLE IV. Multide EBV Strains Within Single Individuals" 
Individual Source Well code EBNA 1 EBNA 2 
P8 
P8 
C24 
C24 
C24 
C25 
C25 
C25 
C25 
C27 
C27 
PB 
PB 
PB 
PB 
PB 
PB 
PB 
PB 
sv 
PB 
sv 
G2" 
G8 
D10 
E l 0  
F7 
B5 
D9 
G6' 
B10 
C8 
D3 
87b 
78 
85 
85 
92 
83 
91 
79 
78 
83 
91 
85 
90 
86 
86 
90 
90 
88 
88 
90 
89 
88 
EBNA 6 
146 
144 
149 
149 
157 
148 
145 
146 
143 
- 
- 
LMP 1 
57 
62 
66 
66 
64 
62 
65 
62 
62 
60 
63 
"PB, peripheral blood; SV, saliva. 
"The same Ebnotype was observed in 5 additional LCL obtained from the peripheral blood. 
bEstimated MW in kD. 
"The same Ebnotype was observed in 6 additional LCL obtained from the peripheral blood. 
that were negative for transforming or Raji-superin- 
fecting activity were also PCR negative; the PCR used 
has a detection limit of 10 EBV genome copies [I. Ern- 
berg, personal communication]. An alternative expla- 
nation would be the generation of defective EBV parti- 
cles with deletions in the BKRFl template of our PCR. 
The spectrum of Type A EBV strains that  could be 
characterized on the basis of outgrowing LCL is most 
likely an  underestimate of the variety of EBV strains 
carried by the patients and control persons. Establish- 
ment of permanently growing LCL was particularly 
difficult from the peripheral blood cultures of pSS pa- 
tients and from the salivary cultures of the control per- 
sons. First, Type B EBV strains, known to have poor 
transforming capability [Rickinson, e t  al., 19871, may 
have been involved in these cases. We investigated this 
possibility by following the approach of Sculley et al. 
[19901 who extrapolated the carrier status of Type B 
EBV strains from the presence of Type B EBNA 2 anti- 
bodies. Indeed, 4 of 18 SS patients with Type B EBNA 2 
antibodies were identified; from none of them could 
permanently growing LCL be established. Second, EBV 
strains with EA-inducing capability may be prevalent 
in parotid saliva. This contention is supported by the 
relatively high frequency of detection of EA-inducing 
virus (8 of 12 control persons) as  compared to the estab- 
lishment of permanently growing LCL from salivary 
cultures (4 of 12 control persons). 
Although the spectrum of characterized EBV strains 
is probably skewed by the type of virus isolation proce- 
dure, i.e., B lymphocyte transformation, 2 interesting 
observations were made. First, 4 unrelated individuals 
shared one particular EBV strain. This strain was iso- 
lated from the saliva of control persons C20, C21, and 
C25, and was present in 1 of the 7 LCL derived from 
Patient P8's blood. The sharing of identical EBV 
strains by unrelated individuals has not been observed 
in our previous studies on more than 40 EBV carriers 
[Gratama et al., 1990a,b; 19921. However, these studies 
were based on EBV isolations from peripheral blood 
and mouthwash samples and did not include selective 
samplings from the parotid gland. The present observa- 
tion may be explained by preferential homing of the 
shared EBV strain in the salivary gland epithelium 
and its presence in the B lymphocyte compartment as a 
minority strain. Interestingly, Niedobitek et al. [1991 J 
detected an  identical 66 kD EBNA 1 band in immuno- 
blots of 14 specimens derived from oral hairy leuko- 
plakia lesions. Our data and those of Niedobitek et al. 
[1991] suggest that certain EBV strains are tropic for 
epithelial cell types, in analogy with the organ-specific 
selection of variants of murine chronic lymphocytic 
choriomeningitis virus infection [Ahmed and Oldstone, 
19881. 
Second, 4 individuals carried multiple Type A 
strains. Previous work [Yao et al., 1991; Gratama et al., 
19921 has shown the dominance of a single transform- 
ing EBV strain in healthy virus carriers. Multiple 
transforming EBV strains were encountered in some 
recipients of bone marrow allografts. Two patterns of 
multiple EBV strain carriage were observed: a) coexist- 
ence of a Type A and a Type B EBV strain; and b) 
coexistence of multiple minority strains that differed 
from the predominant strain in only a single protein, 
i.e., EBNA 1 [Gratama et al., 19921. The coexistence of 
Type A and B EBV strains has also been documented by 
PCR in the oropharynx of patients infected with the 
human immunodeficiency virus and, less frequently, 
healthy EBV carriers [Morgan et al., 1979; Sixbey et al., 
19891. The present study adds 2 new patterns: a) coex- 
istence of 2 - 4  Type A strains differing in at least 2 of 
the following proteins: EBNA 1, EBNA 2, EBNA 6, and 
LMP 1 (patient P8 and control persons C24, C25, and 
C27); and b) coexistence of a 'variant' Type A strain 
differing only in EBNA 3,4,  and 6 (cf., the E l 0  and D10 
isolates of control person C24). 
One explanation for the coexistence of multiple EBV 
strains within a single individual would be (superlin- 
fection with exogenous strains, either via cell-borne 
virus (through blood transfusions, bone marrow or or- 
gan allografts), or via cell-free virions (through sali- 
vary contacts). As only one of the four carriers of multi- 
ple EBV strains, C25, had received blood transfusions, 
we suggest that superinfection with exogenous EBV 
strains is also possible via salivary transmission. Alter- 
natively, EBV strain diversity may be generated by 
recombination between linear DNA molecules during 
virus replication. Such recombinations would affect the 
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length of repeat sequences, which are present in all 
EBNA coding genes [Baer et al., 19843; for instance, the 
size of EBNA 1 has been shown to correlate positively 
with the length of the coding sequence for the EBNA 1 
Gly-Ala repeat [Hennessy and Kieff, 19831, and that of 
EBNA 6 with the length of a (n x 39) nucleotide repeat 
[Falk et al., in preparation]. EBV replicates predomi- 
nantly in epithelial cells but, to some extent, also in the 
lymphocytic compartment [Rowe et al., 19911. If exoge- 
nous or recombinant virions account for the heteroge- 
neity of EBV carried by the lymphocytes of a single 
individual, such virions would have to gain access to 
the long-term EBV reservoir by transforming lympho- 
cytes in spite of EBV-specific immune surveillance. 
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